Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ANDA "Major/Minor" Amendment Reclassification Proposed By FDA

This article was originally published in The Tan Sheet

Executive Summary

FDA's Office of Generic Drugs may change its classification of ANDA amendments to allow the vast majority to be treated as "minor" amendments receiving 60-day reviews.

You may also be interested in...

FDA’s Generic Priorities: McClellan Lays Out Ambitious Agenda At GPhA

FDA is developing a process to flag NDAs that may pose difficulties for future generic development, Commissioner Mark McClellan, MD/PhD, said at the Generic Pharmaceutical Association annual meeting in Rio Grande, Puerto Rico Jan. 29

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts